Coexistance of JAK2V617F mutation and BCR/ABL translocation in one patient

References (14)

1. Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am Soc Hematol Educ Program 2006
2. 240–5. 2.James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005
3. 1144–8. 3.Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycthemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006
4. 4274–81. 4.Jelinek J, Oki Y, Gharibyan V et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005
5. 3370–3. 5.Bock O, Büsche G, Koop C, Schröter S, Buhr T, Kreipe H. Detection of the single hotspot mutation in the JH2 pseudokinase domain of janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders. Journal of Molecular Diagnostics 2006
6. Krämer A. JAK2-V617F and BCR-ABL-double Jeopardy? Leukemia Res 2008
7. 1489–90. 7.Pardini S, Fozza C, Contini S et al. A case of coexistence between JAK2V617F and BCR/ABL. Eur J Hematol 2008
8. 75–6. 8.Inami M, Inokuchi K, Okabe M et al. Polycthemia associated with the JAK2V617F mutation emerged during treatment of chronic mylogeneous leukemia. Leukemia 2007
9. 1103–4. 9.Cambier N, Renneville A, Cazaentre T et al. JAK2V617F-positive polycythemia vera and philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia 2008
10. 1454–5. 10.Hussein K, Bock O, Seegers E et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disorder with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood 2007
11. 4106–7. 11.Krämer A, Reiter A, Kruth J et al. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukemia. Lancet 2007
12. 658–60. 12.Veronese L, Tchirkov A, Richard-Pebrel C et al. A thrombocytosis occuring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2V617F myeloproliferative neoplasm. Leuk Res 2010
13. 94–6. 13.Campiotti L, Appio L, Solbiati F, AgenoW, Venco A. JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia. Leukemia Research 2009
14. 212–3. 14.Jallades L, Hateyye S, Tigaud I et al. Emergence of therapy-unrelated CML on a backgraund of BCR-ABL-negative J